Currently, there are 3.34B common shares owned by the public and among those 3.34B shares have been available to trade.
The company’s stock has a 5-day price change of -4.53% and -32.37% over the past three months. NVO shares are trading -5.63% year to date (YTD), with the 12-month market performance down to -23.91% lower. It has a 12-month low price of $81.50 and touched a high of $148.15 over the same period. NVO has an average intraday trading volume of 6.64 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -10.86%, -19.49%, and -34.04% respectively.
Institutional ownership of Novo Nordisk ADR (NYSE: NVO) shares accounts for 9.99% of the company’s 3.34B shares outstanding.
It has a market capitalization of $271.01B and a beta (3y monthly) value of 0.46. The stock’s trailing 12-month PE ratio is 26.32, while the earnings-per-share (ttm) stands at $3.08. The company has a PEG of 1.09 and a Quick Ratio of 0.75 with the debt-to-equity ratio at 0.47. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.28% over the week and 2.29% over the month.
Analysts forecast that Novo Nordisk ADR (NVO) will achieve an EPS of 6.38 for the current quarter, 0 for the next quarter and 28.0 for current fiscal year. The lowest estimate earnings-per-share for the quarter is 5.93 while analysts give the company a high EPS estimate of 5.93. Comparatively, EPS for the current quarter was 4.91 a year ago. Earnings per share for the fiscal year are expected to increase by 16.99%, and 22.71% over the next financial year. EPS should grow at an annualized rate of 24.09% over the next five years, compared to 16.48% over the past 5-year period.
Goldman coverage for the Novo Nordisk ADR (NVO) stock in a research note released on May 30, 2024 offered a Buy rating with a price target of $156. BMO Capital Markets was of a view on April 12, 2024 that the stock is Outperform, while Morgan Stanley gave the stock Overweight rating on January 23, 2024, issuing a price target of $120. UBS on their part issued Neutral rating on January 16, 2024.
